Financing channel feed – Endpoints News

Financing channel feed

A biotech startup breaks a 3-year silence, displaying a $65M raise and a next-gen approach to PARP

7 years ago

Deal-hungry Verily secures $1B in fresh funding, months after pressing pause on smart lens project

7 years ago

Juno founders set their sights on creating an ‘epic’ new biotech with high-rolling investors at their back

7 years ago

With early-stage studies underway, Connect Biopharmaceuticals closes $55M round to advance immune modulators

7 years ago

Boyu Capital helps point Celgene-partnered Antengene down a quick path to commercialization

7 years ago

Did Moderna break the biotech IPO market?

7 years ago

The Atlas 5 raise a $250M 'opportunity fund' for later-stage biotech investing

7 years ago

Next-gen T cell player TCR2 Therapeutics sets stage for $100M-plus IPO as MPM's Baeuerle caps prolific year

7 years ago

Backed by a pioneer in BiTE tech, Harpoon marks a course for an IPO and an early display of potential

7 years ago

What other biotech news have you been missing? A big China IPO and more

7 years ago

Fledgling Gossamer sets up an early biotech IPO test for 2019 with a $265M challenge

7 years ago

Biotech billionaire Hiroshi ‘Mickey’ Mikitani doubles down on quest to build a pharma company, closing round at $284M

7 years ago

The year of living large: A fledgling Relay Therapeutics reaps a whopping $400M venture round, with SoftBank pointing the way to a windfall

7 years ago

RiverVest ready to roll with Fund IV after closing the till with $184M

7 years ago

Annexon grabs $75M to pay for push into PhII studies for C1q drugs

7 years ago

GSK, Pfizer to create consumer health powerhouse under JV — then spin it out

7 years ago

Targeting underlying cause of PAH, Cambridge spinout Morphogen-IX raises about $23M in Series B

7 years ago

Entrada launches today, taking a $59M shot at some tough intracellular targets

7 years ago

Jonathan Lim isn't ready to say much about his new startup, but he does have $42M for it

7 years ago

Junshi wins the race for first made-in-China PD-1 approval as execs reap $394M IPO harvest

7 years ago

Versant partners gear up for a $700M bonanza of biotech bets, with a special focus all their own

7 years ago

Harvard prof Omid Farokhzad heads west, setting up a new Bay Area biotech on a mission to start a revolution in pre-symptomatic disease detection

7 years ago

European VC firm Kurma sets its sights on €150 million fund, its biggest ever

7 years ago

Software developer Synthace raises $25.6M to realize 'computer aided biology'

7 years ago

First page Previous page 117 118 119120121 122 123 Next page Last page